Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study

PURPOSE: Fimasartan, the ninth and most recent angiotensin receptor blocker (ARB) approved by the Korea Food and Drug Administration, has shown similar efficacy and safety profiles compared to other ARBs. However, due to being predominantly excreted by the hepatobiliary system, concerns on safety ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Gyu Chul, Joo, Kwon Wook, Kim, Myung-A, Choi, Dong-Ju, Kim, Yoon Jun, Lee, Hae-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138630/
https://www.ncbi.nlm.nih.gov/pubmed/32308367
http://dx.doi.org/10.2147/DDDT.S233174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138630/
https://www.ncbi.nlm.nih.gov/pubmed/32308367
http://dx.doi.org/10.2147/DDDT.S233174

Ejemplares similares